Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s share price rose 7.8% during trading on Monday . The company traded as high as $31.25 and last traded at $30.97, with a volume of 38,084,142 shares trading hands. The stock had previously closed at $28.74.

VRX has been the subject of a number of recent analyst reports. Morgan Stanley restated a “positive” rating on shares of Valeant Pharmaceuticals International in a report on Friday. Royal Bank Of Canada restated a “sector perform” rating and set a $65.00 target price on shares of Valeant Pharmaceuticals International in a report on Monday, May 9th. Jefferies Group restated a “buy” rating and set a $40.00 target price on shares of Valeant Pharmaceuticals International in a report on Wednesday, August 10th. Guggenheim restated a “buy” rating and set a $55.00 target price on shares of Valeant Pharmaceuticals International in a report on Monday, April 25th. Finally, Scotiabank restated a “sector perform” rating and set a $32.00 target price (down previously from $35.00) on shares of Valeant Pharmaceuticals International in a report on Tuesday, July 26th. Six equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $60.32.

The firm’s 50-day moving average is $23.85 and its 200-day moving average is $37.97. The stock’s market capitalization is $10.90 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. The business earned $2.42 billion during the quarter, compared to analyst estimates of $2.47 billion. The business’s revenue was down 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.14 EPS. On average, equities analysts expect that Valeant Pharmaceuticals International Inc. will post $6.54 earnings per share for the current fiscal year.

In related news, Director Argeris N. Karabelas acquired 4,000 shares of the firm’s stock in a transaction dated Thursday, August 11th. The stock was acquired at an average price of $24.65 per share, with a total value of $98,600.00. Following the acquisition, the director now directly owns 20,726 shares in the company, valued at approximately $510,895.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Joseph C. Papa acquired 202,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was bought at an average cost of $24.48 per share, with a total value of $4,944,960.00. Following the acquisition, the chief executive officer now owns 2,442,199 shares in the company, valued at $59,785,031.52. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Valeant Pharmaceuticals International stock. BNP Paribas Arbitrage SA increased its stake in shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) by 253.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 284,308 shares of the specialty pharmaceutical company’s stock after buying an additional 203,760 shares during the period. BNP Paribas Arbitrage SA owned about 0.08% of Valeant Pharmaceuticals International worth $28,900,000 at the end of the most recent quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.